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Background: Mutations in genes that are part of the splicing machinery for myelodysplastic syndromes (MDS),
including MDS without ring sideroblasts (RS), have been widely investigated. The effects of these mutations on
clinical outcomes have been diverse and contrasting.
Methods: We examined a cohort of 129 de novo MDS patients, who did not harbor RS, for mutations affecting
three spliceosomal genes (SF3B1, U2AF1, and SRSF2).
Results: The mutation rates of SF3B1, U2AF1, and SRSF2 were 7.0 %, 7.8 %, and 10.1 %, respectively. Compared with
previously reported results, these rates were relatively infrequent. The SRSF2 mutation strongly correlated with old
age (P < 0.001), while the mutation status of SF3B1 did not affect overall survival (OS), progression-free survival (PFS),
or acute myeloid leukemia (AML) transformation. In contrast, MDS patients with mutations in U2AF1 or SRSF2
exhibited inferior PFS. The U2AF1 mutation was associated with inferior OS in low-risk MDS patients (P = 0.035). The
SRSF2 mutation was somewhat associated with AML transformation (P = 0.083).
Conclusion: Our findings suggest that the frequencies of the SF3B1, U2AF1, and SRSF2 splicing gene mutations in
MDS without RS were relatively low. We also demonstrated that the U2AF1 and SRSF2 mutations were associated
with an unfavorable prognostic impact in MDS patients without RS.
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The myelodysplastic syndromes (MDS) represent mye-
loid clonal hemopathies, with a relatively heterogeneous
spectrum of presentation. The major clinical problems
of these disorders are morbidities caused by cytopenias
and the potential for MDS to evolve into acute myeloid
leukemia (AML) [1]. Although cytopenias represent the
major clinical challenge in low-risk disease, transform-
ation to AML is observed in a significant number of
high-risk MDS patients.* Correspondence: mgshin@chonnam.ac.kr
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creativecommons.org/publicdomain/zero/1.0/The broad range of individual genes affected by muta-
tions indicates that a variety of molecular mechanisms
are involved in the pathogenesis of MDS [2]. A number
of gene mutations and cytogenetic changes have been
implicated in the pathogenesis of MDS, including muta-
tions in RAS, TP53, and RUNX1. However, mutations in
these genes do not fully explain the pathogenesis of
MDS as these mutations are also commonly found in
other myeloid malignancies. In addition, approximately
20 % of MDS cases are not associated with any genetic
changes. The genetic alterations responsible for dysplas-
tic phenotypes and ineffective hematopoiesis of myelo-
dysplasia are poorly understood [3].
A previous report by Murati et al. [4] described that
mutations in components of the spliceosome, which are
mutually exclusive, lead to splicing defects, including
exon skipping, intron retention, and the use of incorrectcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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mal genes is the accumulation of unspliced transcripts
that affect a specific subset of mRNAs. According to
Yoshida et al. [3] and Makishima et al. [5], mutations af-
fecting spliceosomal genes that result in defective spli-
cing could belong to a new leukemogenic pathway, and
these mutations might constitute diagnostic biomarkers
that could serve as therapeutic targets.
A recent study by Damm et al. [2] revealed that splice
gene mutations are among the most frequent molecular
aberrations in MDS. They might define distinct clinical
phenotypes and show preferential association for muta-
tions targeting transcriptional regulation. These genoty-
pe—phenotype associations have been demonstrated for
somatic spliceosomal gene mutations in MDS with ring
sideroblasts (RS). Although there have been a number of
studies investigating spliceosomal mutations in MDS
without RS, the effects of these mutations on clinical
outcomes have not been uniform.
We investigated the prevalence and clinical impact of
mutations in splicing factor 3 subunit b1 (SF3B1), U2
small nuclear RNA auxiliary factor 1 (U2AF1), and serine
arginine-rich splicing factor 2 (SRSF2) among a cohort of
MDS patients without RS.
Methods
Patients
From 2003–2011, 129 adult patients with de novo MDS, di-
agnosed according to World Health Organization (WHO)
2008 criteria, at Chonnam National University Hwasun
Hospital (Hwasun, Korea) were enrolled into this study.
The patient cohort comprised 129 MDS patients without
RS. A detailed summary of the enrolled patients is shown
in Table 1. Of the 129 MDS patients, 58 received treatment
with hypomethylating agents (42 received azacitidine and
16 received decitabine), while 11 patients underwent
allogeneic hematopoietic stem cell transplantation (allo-
HSCT). For the MDS patients that were treated with
hypomethylating agents or allo-HSCT, this occurred prior
to 2012. Therefore, we were unable to use the revised
International Prognostic Scoring System (IPSS-R) [6] to
decide upon treatment. Using the original International
Prognostic Scoring System (IPSS), the treatment indica-
tions for hypomethylating agents or allo-HSCT were:
(1) intermediate-1 with anemia, despite treatment with
erythropoietin; (2) intermediate-1 with anemia accom-
panying other cytopenia (neutrophils < 1 × 103/μl or
platelets < 100 × 103/μl); and (3) intermediate-2 or high risk.
Azacitidine was administered subcutaneously at a dose of
75 mg/m2 per day for seven consecutive days, every 28 days.
Decitabine was administered intravenously at a dose of
20 mg/m2 per day for five consecutive days, every 28 days.
When we retrospectively applied the IPSS-R for treated pa-
tients (n = 58), 3.5, 24.1, 29.3, 29.3, and 13.8 % of patientswere considered to be at very low, low, intermediate, high,
and very high risk, respectively. Clinical and laboratory data
for MDS patients were analyzed and reviewed, based on
their electronic medical records. All enrolled MDS patients
gave their written, informed consent in accordance with the
Declaration of Helsinki. This study was approved by the
institutional review board of Chonnam National University
Hwasun Hospital.
Mutation analyses of spliceosomal genes
Genomic DNA from each MDS patient was extracted using
the AccuPrep Genomic DNA Extraction Kit (Bioneer, Dae-
jeon, Korea) according to the manufacturer’s instructions.
The detection of mutations in SF3B1, U2AF1, and SRSF2
was conducted using polymerase chain reaction (PCR)
followed by direct sequencing. For direct sequencing
of the spliceosomal genes, six primer pairs were used
(Additional file 1: Table S1) according to a published proto-
col (Additional file 2), with some minor modifications.
Gene sequences were compared using Blast2 (http://
blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&
BLAST_SPEC=blast2seq&LINK_LOC=align2seq) to obtain
preliminary evidence regarding polymorphisms, mutations,
and for translation of amino acids. Results obtained from
MDS patients were confirmed on an online database (http://
genewindow.nci.nih.gov/Welcome; Additional file 2). The
aberrant status of SF3B1, U2AF1, and SRSF2, was confirmed
by TA cloning (Fig. 1) using the pGEM-T Easy vector (Pro-
mega, Madison, WI, USA). For each spliceosomal gene,
three MDS patients representative of the typical heterozy-
gous form of the gene were selected (Additional file 2).
Cytogenetic analysis
Chromosomal analysis (G-banding) was performed on
preparations from 48-h bone marrow cell cultures where
mitogens were not added, according to a protocol from the
American Type Culture Collection. Aberrations in chromo-
somes were described according to the international system
for cytogenetic nomenclature 2005 and 2009.
Statistical analyses
The χ2 test or Fisher’s exact test was performed to deter-
mine the significance of associations between SF3B1,
U2AF1, and SRSF2 mutations and other parameters, in-
cluding sex, WHO classification, karyotypes, and IPSS-R
risk classification. Student’s t-test was used to compare
continuous variables such as age and hemograms. Kaplan-
Meier estimation was used to plot survival curves, and log-
rank tests were used to calculate the difference between
survival curves. Cox proportional hazard regression ana-
lysis was used to dissect the individual impact of prognostic
factors for overall survival (OS), progression-free survival
(PFS), and acute myeloid leukemia (AML) transformation.
All tests were two-tailed, and a P-value of less than 0.05
Table 1 Clinical characteristics of 129 MDS patients based on the mutation status of spliceosomal genes
Characteristics SF3B1wt
(n = 120, 93.0 %)
SF3B1mut
(n = 9, 7.0 %)
P U2AF1wt
(n = 119, 92.2 %)
U2AF1mut
(n = 10, 7.8 %)
P SRSF2wt
(n = 116, 89.9 %)
SRSF2mut
(n = 13, 10.1 %)
P
Age (years)a 63.4 ± 11.9 67.9 ± 19.1 0.295 63.6 ± 12.5 63.8 ± 11.8 0.975 62.8 ± 12.7 71.5 ± 5.5 0.000
Sex 0.730 0.183 0.381
Male, n (%) 67 (55.8) 4 (44.4) 63 (52.9) 8 (80.0) 62 (53.4) 9 (70.2)
Female, n (%) 53 (44.2) 5 (55.6) 56 (47.1) 2 (20.0) 54 (46.6) 4 (30.8)
Blood countsa
WBC (× 103/μl) 5.6 ± 14.3 3.7 ± 1.8 0.700 5.5 ± 14.4 5.1 ± 4.6 0.935 5.6 ± 14.6 4.2 ± 2.7 0.734
Neutrophil (× 103/μl) 3.4 ± 12.0 1.5 ± 1.3 0.650 3.2 ± 12.1 3.4 ± 3.9 0.960 3.4 ± 12.3 1.9 ± 1.9 0.672
Hemoglobin (g/dl) 9.7 ± 2.2 9.2 ± 2.3 0.556 9.7 ± 2.2 8.4 ± 2.0 0.063 9.7 ± 2.3 9.4 ± 1.8 0.657
Platelet (× 103/μl) 95 ± 91 168 ± 151 0.183 100 ± 98 92 ± 87 0.806 100 ± 100 91 ± 67 0.734
Bone marrow blasts (%) 5.3 ± 5.3 3.8 ± 5.0 0.398 5.0 ± 5.2 7.7 ± 6.2 0.123 5.2 ± 5.4 5.6 ± 4.3 0.783
WHO subtype, n (%) 0.303 0.516 0.094
RCUD 18 (15.0) 1 (11.1) 19 (16.0) 0 (0.0) 18 (15.5) 1 (7.7)
RCMD 51 (42.5) 5 (55.6) 52 (43.7) 4 (40.0) 50 (43.1) 6 (46.2)
RAEB-1 15 (12.5) 1 (11.1) 13 (10.9) 3 (30.0) 11 (9.5) 5 (38.5)
RAEB-2 29 (24.2) 1 (11.1) 27 (22.7) 3 (30.0) 29 (25.0) 1 (7.7)
MDS-U 1(0.8) 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.9) 0 (0.0)
MDS associated with isolated del(5q) 1 (0.8) 1 (11.1) 2 (1.7) 0 (0.0) 2 (1.7) 0 (0.0)
Hypoplastic MDS 5 (4.2) 0 (0.0) 5 (4.2) 0 (0.0) 5 (4.3) 0 (0.0)
Karyotype, n (%) 0.013 0.022 0.048
Normal 87 (72.5) 6 (66.7) 87 (73.1) 6 (60.0) 86 (74.1) 7 (53.8)
-Y only 3 (2.5) 0 (0.0) 3 (2.5) 0 (0.0) 3 (2.6) 0 (0.0)
−5 or del(5q) 2 (1.7) 1 (11.1) 3 (2.5) 0 (0.0) 3 (2.6) 0 (0.0)
del(11q) 1 (0.8) 0 (0.0) 1 (0.9) 0 (0.0) 0 (0.0) 1 (7.7)
del(20q) 0 (0.0) 1 (11.1) 1 (0.9) 0 (0.0) 1 (0.9) 0 (0.0)
−7 1 (0.8) 0 (0.0) 0 (0.0) 1(10.0) 1 (0.9) 0 (0.0)
Complex (≥3) 11 (9.2) 0 (0.0) 11 (9.2) 0 (0.0) 8 (6.9) 3 (23.1)
Other 15(12.5) 1 (11.1) 13 (10.9) 3 (30.0) 14 (12.0) 2 (15.4)
IPSS-R risk classification, n (%) 0.133 0.270 0.505











Table 1 Clinical characteristics of 129 MDS patients based on the mutation status of spliceosomal genes (Continued)
Low 25 (20.8) 5 (55.6) 29 (24.4) 1 (10.0) 29 (25.0) 1 (7.7)
Intermediate 40 (33.3) 2 (22.2) 39 (32.8) 3 (30.0) 36 (31.0) 6 (46.2)
High 31 (25.8) 0 (0.0) 26 (21.8) 5 (50.0) 28 (24.1) 3 (23.1)
Very high 10 (8.3) 1 (11.1) 10 (8.4) 1 (10.0) 9 (7.8) 2 (15.3)
aMean ± SD
Statistical significance is indicated by boldface type
wt, wild type; mut, mutated; WBC, white blood cell; WHO, World Health Organization; MDS, myelodysplastic syndrome; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with











Fig. 1 Sequencing chromatograms showing mutations in spliceosomal genes. Direct sequencing and TA cloning methods confirmed the heterozygous
mutations in SF3B1 a, U2AF1 b, and SRSF2 c
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lyses were performed using PASW version 18.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Mutation status of SF3B1, U2AF1, and SRSF2 in MDS patients
Mutations in one of the spliceosomal genes (SF3B1,
U2AF1, and SRSF2) were observed in 24.8 % (32/129) of
MDS patients . Among the 129 MDS patients, nine were
identified as harboring a mutation in SF3B1 (7.0 %), 10
patients had mutations in U2AF1 (7.8 %), and 13 pa-
tients exhibited a mutation in SRSF2 (10.1 %). All 129
MDS patients in this study were without RS. The SF3B1,
U2AF1, and SRSF2 mutations were mutually exclusive,
with none of the patients having more than one of these
genes affected (Tables 1 and 2). The mutations in SF3B1,
U2AF1, and SRSF2 were all heterozygous point muta-
tions (n = 32; Table 2). The aberrant status of SF3B1,
U2AF1, and SRSF2 was confirmed by TA cloning and
direct sequencing (Fig. 1).
Patient characteristics with respect to SF3B1, U2AF1, and
SRSF2 mutation status
The clinical and hematological characteristics of patients
with mutated (mut) versus wild-type (wt) SF3B1, U2AF1,
and SRSF2 are shown in Table 1. Patients with SF3B1
mutations showed significant differences in karyotype
(P = 0.013). Positive cytogenetic findings, such as normal
karyotype, −Y only, del(5q) alone, and del(20q) alone
were more frequent in SF3B1mut patients than in
SF3B1wt patients (88.9 vs. 75.8 %). Poor cytogenetic find-
ings, such as complex karyotype, and abnormalities in
chromosome 7 were more apparent in SF3B1wt patients
than in SF3B1mut patients (10.0 vs. 0 %). There were no
significant differences in age, sex, blood counts, bone
marrow blasts, WHO subtype, and IPSS-R risk classifi-
cation between SF3B1mut and SF3B1wt patients. Never-
theless, lower risk MDS patients, such as those withTable 2 Mutations in spliceosomal genes of MDS patients and
the resulting acid changes
Gene Mutation Amino acid change Frequency (%)
SF3B1 Exon 14 c.1998G > C p.Lys666Asn 1/129 (0.8)
c.1986C > G p.His662Gln 1/129 (0.8)
Exon 15, 16 c.2098A > G p.Lys700Glu 7/129 (5.4)
Exon 18 No mutation No mutation
U2AF1 Exon 2 c.101C > A p.Ser34Tyr 2/129 (1.6)
c.101C > T p.Ser34Phe 3/129 (2.3)
Exon 6, 7 c.470A > C p.Gln157Pro 5/129 (3.9)
SRSF2 Exon 1 c.284C > A p.Pro95His 6/129 (4.7)
c.284C > G p.Pro95Arg 4/129 (3.1)
c.284C > T p.Pro95Leu 3/129 (2.3)refractory cytopenia with unilineage dysplasia (RCUD)
or refractory cytopenia with multilineage dysplasia
(RCMD), were represented in higher proportions among
SF3B1mut patients than SF3B1wt patients (66.7 vs.
57.5 %). For higher risk MDS patients, such as those
with refractory anemia with excess blasts-1 (RAEB-1) or
RAEB-2, there was a lower proportion of SF3B1mut pa-
tients than SF3B1wt patients (22.2 vs. 36.7 %).
Patients harboring mutations in U2AF1 were mainly
male (8/10) and exhibited lower hemoglobin levels (mean:
8.4 vs. 9.7 g/dL for U2AF1mut vs. U2AF1wt; P = 0.063). Our
cytogenetic results revealed meaningful differences be-
tween U2AF1mut and U2AF1wt patients (P = 0.022). Posi-
tive cytogenetic findings were more frequently observed
for U2AF1wt than U2AF1mut patients (78.3 vs. 60.0 %),
while poor cytogenetic findings were more common in
U2AF1mut patients (10.0 vs. 9.2 %). In contrast, no signifi-
cant differences were identified between U2AF1mut and
U2AF1wt patients for age, sex, blood counts, bone marrow
blasts, WHO subtype, and IPSS-R risk classification. The
higher risk MDS patients (RAEB-1 or RAEB-2) were
more likely to be U2AF1mut patients (60.0 vs. 33.6 %),
while lower risk MDS patients (RCUD or RCMD) were
less likely to be U2AF1mut individuals (40.0 vs. 59.7 %)
(P = 0.629).
The SRSF2mut patients were older than SRSF2wt pa-
tients (mean: 71.5 vs. 62.8 years; P < 0.001) and mostly
male (9/13). Similar to the U2AF1mut patients, those
with SRSF2 mutations displayed a significant difference
in cytogenetic results (P = 0.048). Good cytogenetic find-
ings were more frequently seen for SRSF2wt patients
(79.4 vs. 53.8 % in SRSF2mut patients), while poor cytogen-
etic findings were more common for SRSF2mut patients
(23.1 vs. 7.8 % in SRSF2wt patients). We observed no sig-
nificant differences in sex, blood counts, bone marrow
blasts, WHO subtype, and IPSS-R risk classification be-
tween SRSF2mut and SRSF2wt patients. The higher risk
MDS patients (RAEB-1 or RAEB-2) were more likely to
be SRSF2mut patients (46.2 vs. 34.5 %), while lower risk
MDS patients (RCUD or RCMD) were less likely to be
SRSF2mut patients (53.9 vs. 58.6 %) (P = 0.094).
Prognostic impact of SF3B1, U2AF1, and SRSF2 mutations
We investigated the effects of each spliceosomal muta-
tion on clinical outcomes. Using univariate analyses, OS
and AML transformation rates according to the muta-
tion status of the three genes were not significant
(Table 3). An inferior PFS was seen for U2AF1mut pa-
tients (HR = 4.409; 95 % CI, 1.174–16.558; P = 0.033)
and SRSF2mut patients (HR = 3.878; 95 % CI, 1.181–
12.726; P = 0.018).
The IPSS-R was used to derive clinical prognosis for
MDS. To establish whether the mutation status of spliceo-
somal genes can add to the predictive power of IPSS-R,
Table 3 Univariate analysis for overall survival (OS), progression-free survival (PFS), and AML transformationa
OS PFS AML transformation
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Age (>60 years vs. ≤ 60 years) 0.964 0.374–2.487 0.940 1.295 0.516–3.252 0.581 0.924 0.290–2.945 0.893
IPSS-R risk groupsb, higher vs. lower 5.600 1.453–21.583 0.010 5.864 1.186–28.982 0.023
SF3B1c (mut vs. WT) 1.347 0.261–6.947 0.662 0.452 0.054–3.779 0.684
U2AF1 (mut vs. WT) 1.167 0.231–5.893 1.000 4.409 1.174–16.558 0.033 0.906 0.106–7.737 1.000
SRSF2 (mut vs. WT) 0.823 0.170–3.989 1.000 3.878 1.181–12.726 0.018 2.864 0.684–11.989 0.151
Statistical significance is indicated by boldface type
aUnivariate analysis of OS, PFS, and AML transformation was performed by two-sided Fisher’s exact test or χ2 test
bIPSS-R higher indicates very high risk or high risk, and IPSS-R lower indicates low risk or very low risk
cFor the IPSS-R lower risk group or SF3B1mut patients, no AML transformation was found
AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; IPSS-R, revised International Prognostic Scoring System; mut, mutated; WT, wild-type
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examining age, sex, IPSS-R total score, and SF3B1/
U2AF1/SRSF2 mutation status (Table 4). The IPSS-R total
score strongly correlated with OS, PFS, and AML trans-
formation, while the mutation status of U2AF1 (HR =
4.840; 95 % CI, 1.655–14.157; P = 0.004) and SRSF2 (HR =
4.379; 95 % CI, 1.604–11.952; P = 0.004) remained an in-
dependent predictor for PFS. AML transformation was
not associated with the mutation status of SF3B1.
We evaluated OS, PFS, and AML probabilities accord-
ing to the mutation status of spliceosomal genes in all
MDS patients (Fig. 2a–i), and subgroups of MDS patients
(Fig. 3a–d), using Kaplan-Meier estimation. No differences
in survival were seen for all MDS patients with or without
mutations in SF3B1 (Fig. 2a, d, and g). Patients carrying a
mutation in U2AF1 (P = 0.009; Fig. 2e) or SRSF2 (P = 0.001;
Fig. 2f) exhibited significantly lower PFS compared with
wild-types. The presence of a SRSF2 mutation was a some-
what unfavorable prognostic factor for AML transformation
(P = 0.054; Fig. 2i).
MDS subgroup analysis revealed that the poor impact
of a U2AF1 mutation on OS was only demonstrated in
the lower risk groups (very low and low) defined by IPSS-
R (P = 0.035; Fig. 3a). In addition, patients harboring the
U2AF1 mutation showed inferior PFS in the higher riskTable 4 Cox regression analysis for overall survival (OS), progression
OS
HR 95 % CI P HR
Age (years) 1.029 0.987–1.073 0.174 1.039
Sex (male vs. female) 0.711 0.298–1.695 0.442 0.881
IPSS-R total score 1.634 1.263–2.115 <0.0001 1.546
SF3B1b (mut vs. WT) 2.663 0.572–12.397 0.212 1.533
U2AF1 (mut vs. WT) 1.648 0.365–7.436 0.516 4.840
SRSF2 (mut vs. WT) 1.216 0.270–5.485 0.799 4.379
Statistical significance is indicated in boldface type
aMultivariate analysis of OS, PFS, and AML transformation was performed using a C
score, and mutation status of SF3B1, U2AF1, and SRSF2
bFor SF3B1mut patients, no AML transformation was seen
AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; IPSS-R, revisegroups (RAEB-1 or RAEB-2) defined by WHO 2008 cri-
teria (P = 0.045; Fig. 3b). Patients with the SRSF2 mutation
showed inferior PFS in the lower risk groups (RCUD or
RCMD) defined by WHO 2008 criteria (P = 0.004; Fig. 3c).
Patients with a SRSF2 mutation exhibited a somewhat in-
creased rate for AML transformation among lower risk
(RCUD or RCMD) MDS patients (P = 0.083; Fig. 3d). No
survival differences were seen between MDS patients with
or without the SF3B1 mutation (data not shown).
Discussion
Recent reports regarding whole exome sequencing in
MDS patients by Yoshida et al. [3] and Papaemmanuil
et al. [7] suggest that spliceosome mutations have some
clinical relevance. Identifying the impact of these muta-
tions on MDS pathogenesis holds some promise for the
therapeutic modulation of mRNA splicing [8]. The exact
functional consequences of these spliceosomal mutations in
MDS pathogenesis and other hematological malignancies
remain largely unknown, and are being intensely investi-
gated [9]. The molecular diversity of MDS corresponds to
the clinical and phenotypic heterogeneities of these syn-
dromes. Moreover, molecular defects could potentially
serve as biomarkers for the identification of therapeutic tar-
gets [5]. To date, these genotype–phenotype associations of-free survival (PFS), and AML transformationa
PFS AML transformation
95 % CI P HR 95 % CI P
0.996–1.084 0.074 1.007 0.952–1.064 0.819
0.388–1.999 0.761 0.823 0.266–2.553 0.737
1.214–1.969 <0.0001 1.699 1.200–2.405 0.003
0.193–12.145 0.686
1.655–14.157 0.004 1.252 0.149–10.494 0.836
1.604–11.952 0.004 2.672 0.697–10.245 0.152
ox proportional hazards regression model that included age, sex, IPSS-R total
d International Prognostic Scoring System; mut, mutated; WT, wild-type
Fig. 2 Clinical outcomes are affected by the mutation status of spliceosomal genes. Kaplan-Meier analysis of overall survival a–c, progression-free survival
d–f, and probability of AML transformation g–i for the total MDS patient cohort (n = 129), stratified according to SF3B1, U2AF1, and SRSF2
mutation status. AML, acute myeloid leukemia; wt, wild-type; mut, mutant
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merous researchers have investigated spliceosomal muta-
tions in MDS without RS; however, the effects of these
mutations on clinical outcomes have not been uniform. We
investigated the prevalence and prognostic implication of
the SF3B1, U2AF1, and SRSF2 mutations in MDS patients
without RS from Korea.
Our findings indicate that the SF3B1, U2AF1, and
SRSF2 mutations were relatively infrequent in MDS pa-
tients without RS, contradicting the results from a previ-
ous study. In addition, our results demonstrate that theU2AF1 and SRSF2 mutations, unlike SF3B1, were associ-
ated with a negative prognostic impact for MDS patients
without RS.
Spliceosomes in the nucleus are complexes composed
of small nuclear RNAs (snRNA) and numerous protein
subunits. These spliceosomes serve to remove introns
from genes that encode proteins [10]. Identifying these
genes and understanding the mechanisms involved in
aberrant splicing might lead to advancements in diagnosis
and treatment of MDS and other diseases [11]. According
to a recent report by Makishima et al., mutations affecting
Fig. 3 Impact of U2AF1 a–b and SRSF2 c–d mutations on the clinical outcome of the MDS subgroups. Overall survival a and progression-free
survival b–c are affected by U2AF1 or SRSF2 genotypes according to subgroup analysis of MDS patients. The probability of AML progression was
increased for RCUD and RCMD patients with a mutation in SRSF2 d. AML, acute myeloid leukemia; IPSS-R, revised International Prognostic Scoring
System; mut, mutant; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia
with unilineage dysplasia; wt, wild-type
Kang et al. BMC Cancer  (2015) 15:484 Page 9 of 11spliceosomal genes that result in defective splicing belong
to a new leukemogenic pathway, with these mutations
possibly constituting diagnostic biomarkers that could be
therapeutic targets [5].
These spliceosomal gene mutations occur at varying
frequencies for different disease subtypes, and contribute
to differences in survival outcomes [9]. The SF3B1 gene
is located on chromosome 2q33.1 and codes for the
SF3B1 protein complex, which is involved in the earlystages of spliceosome assembly. U2AF1 gene is located
on chromosome 21q22, and encodes proteins that play a
role in the early steps of 3′ splice site recognition. The
SRSF2 gene is located on chromosome 17q25.2, with the
coding protein known to play a role in preventing exon
skipping and ensuring the accuracy of splicing [12].
It was previously reported that the incidence of MDS
with RS is far less common than that of MDS without
RS in the Korean population [13, 14]. Consistent with
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MDS patients without RS. For this cohort, the muta-
tion rates of SF3B1, U2AF1, and SRSF2 were 7.0, 7.8,
and 10.1 %, respectively (Table 1). The occurrence of
mutations in these genes, for MDS patients without
RS, were relatively infrequent compared with that seen
in earlier studies [3, 8, 9, 14]. Hahn and Scott reported
that the p.Lys700Glu was the most recurrently occur-
ring alteration in both MDS and chronic lymphocytic
leukemia [10]. In the current study, this particular
mutation was the most common seen in spliceosomal
genes likewise (Table 2).
Malcovati et al. reported that only 5.3 % (2/38) of
patients with AML evolving from MDS carried a som-
atic mutation in SF3B1 [15]. In our current study,
none of the SF3B1mut MDS patients progressed into
AML, and these patients were more likely to present
with advantageous cytogenetic findings. However,
U2AF1mut and SRSF2mut patients were considered to
belong to higher risk MDS groups or to have a poor
cytogenetic findings (Table 1).
We also found that the U2AF1 mutation mainly occurred
in males and correlated with relatively low hemoglobin
levels. It was previously that mutations in U2AF1 confer
the suppression of growth in vitro [3], possibly contributing
to the cytopenias seen in U2AF1mut patients within the
current MDS cohort. Occurrence of the SRSF2 mutation
strongly correlated with older individuals (P < 0.001), simi-
lar to the findings of Wu et al. [16] (Table 1).
We found that the IPSS-R total score had a strong
association with OS, PFS, and AML transformation
(Table 4). However, the prognostic impact of spliceo-
some gene mutations in MDS patients remains
controversial [16]. Some studies have reported that
SF3B1 mutations are a marker of favorable outcomes
for MDS [7, 15]. However, results from other studies
[17], including our analysis in the current study, indi-
cate that SF3B1 mutations do not represent an inde-
pendent prognostic factor (Tables 3 and 4, Fig. 1).
These differences could be attributed to the hetero-
geneity of the disease itself, the composition of patient
populations, and the various treatment strategies used
[17, 18].
Regarding the U2AF1 mutation, results from one
study concluded that it did not influence OS [19], while
another report claimed that it was associated with
shorter OS [5]. Analysis of our whole cohort, or even
subgroup analysis of MDS patients, revealed inferior
OS and PFS for U2AF1mut patients (Figs. 2e and 3a–b).
This negative prognostic impact for PFS was also seen
when we conducted univariate or multivariate Cox re-
gression analysis (Tables 3 and 4), further supporting
the idea that the U2AF1 mutation could be an inde-
pendent prognostic marker for MDS.The SRSF2 mutation negatively affected PFS in MDS
patients, especially for those in the lower risk MDS
groups (Figs. 2f and 3c). We also found that the SRSF2
mutation was an independent prognostic factor for a
poor PFS outcome (Tables 3 and 4). Consistent with
findings by Thol et al., who reported that SRSF2 muta-
tions were associated with an increased risk of progres-
sion to AML [18], we observed a somewhat significant
impact of the SRSF2 mutation on the progression time
to AML transformation (Figs. 2i and 3d). In a previous
study, deletion of SRSF2 contributes to genomic instabil-
ity, which is a predictive marker for adverse outcomes in
MDS, and possibly explains why SRSF2 mutations confer
a strong adverse effect [18].Conclusions
In summary, we observed that mutations in SF3B1,
U2AF1, and SRSF2, in MDS patients without RS, were
relatively infrequent molecular events. The mutation sta-
tus of SF3B1 was not associated with OS, PFS, or AML
transformation, regardless of the groupings used in our
analyses. In contrast, all U2AF1mut and SRSF2mut pa-
tients displayed inferior PFS. We observed that muta-
tions in U2AF1 were associated with inferior OS in the
lower risk MDS groups defined by IPSS-R (very low or
low risk) and that there was somewhat of an association
between AML transformation and mutations in SRSF2.Additional files
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